CVRx Revenue and Competitors
Estimated Revenue & Valuation
- CVRx's estimated annual revenue is currently $11.5M per year.
- CVRx's estimated revenue per employee is $39,965
- CVRx's total funding is $390.6M.
- CVRx's current valuation is $192.7M. (January 2022)
Employee Data
- CVRx has 287 Employees.
- CVRx grew their employee count by 23% last year.
CVRx's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CFO | Reveal Email/Phone |
2 | VP, Market Access and Direct to Consumer Marketing | Reveal Email/Phone |
3 | VP, Quality Assurance and Regulatory Affairs | Reveal Email/Phone |
4 | VP Operations | Reveal Email/Phone |
5 | VP Global Clinical Research | Reveal Email/Phone |
6 | VP, General Counsel | Reveal Email/Phone |
7 | SVP US Sales | Reveal Email/Phone |
8 | Controller | Reveal Email/Phone |
9 | VP European Sales and Marketing | Reveal Email/Phone |
10 | Director Clinical Affairs | Reveal Email/Phone |
CVRx Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $20.5M | 132 | 8% | $1.4B | N/A |
What Is CVRx?
CVRx is a private company located in Minneapolis, Minnesota. The company has developed proprietary implantable technology for the treatment of high blood pressure and heart failure. The Barostim neo? uses CVRx-patented technology that is designed to trigger the body?s own natural blood flow regulation system to treat these conditions. The Barostim neo can be adjusted to meet each patient?s individual therapy needs.
keywords:Biotechnology
$390.6M
Total Funding
287
Number of Employees
$11.5M
Revenue (est)
23%
Employee Growth %
$192.7M
Valuation
N/A
Accelerator
CVRx News
CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for...
("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation...
CVRx boosted investment sharply in the last year, with cash burn ramping by 76%. Of course, the truly verdant revenue growth of 115% in that...
CVRx’s Barostim Neo [Image courtesy of CVRx]CVRx has raised $50 million in its latest round of equity financing — money the company will use to support the U.S. commercialization of its Barostim Neo heart failure treatment device. New investors Strategic Healthcare Investment Partners and Vensa ...
“Barostim Therapy is designed to activate the Baroreflex through the afferent (sensory) pathway causing a simultaneous reduction in sympathetic activity and increase in parasympathetic activity. Restoring autonomic balance leads to a reduction in symptoms and has the potential to significantly i ...
Other Companies in Minneapolis
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $79.5M | 288 | 21% | N/A |
#2 | $44.5M | 289 | 6% | N/A |
#3 | $85.8M | 289 | 40% | N/A |
#4 | $85.8M | 289 | 40% | N/A |
#5 | $86.1M | 290 | 7% | N/A |